Circassia has a broad development portfolio of treatments for asthma and chronic obstructive pulmonary disease (COPD). Many of the products are based on our proprietary technologies, which provide a number of important potential benefits.

Asthma therapies

Our particle-engineered treatments target direct substitution of several market-leading asthma products.

COPD treatments

A number of our COPD therapies leverage the company’s proprietary particle-engineering technologies, which offer the potential to develop novel formulations.